CAR T cell therapies targeting B7-H3 (CD276), a marker expressed on DIPG tumors, have been tested in early phase clinical trials and demonstrated feasibility and tolerability. [...] However, many CAR T cells may struggle to travel into the tumor and exert their cancer-killing effects. Read more: https://www.fredhutch.org/en/news/spotlight/2026/01/ccsg-song-natcomm.html

BrainChild Bio, Inc., a clinical-stage biotechnology company developing CAR T-cell therapies to treat tumors in the central nervous...

CAR-T cell therapy has significantly improved outcomes for B-ALL patients, but relapse still occurs in over 50% of cases, leaving many...

In an early-stage clinical trial, the therapy nearly doubled the expected survival time of young patients. Still, experts caution that...

Treatment with bicistronic CD19/CD22 CAR-T cell therapy has shown event-free survival improvements in children with relapsed or...

CAR-T cells show promise against pediatric diffuse midline gliomas, brain and spinal cord tumors that are among the deadliest cancers, a...

Youngsters with T-cell acute lymphoblastic leukaemia (T-ALL) will be offered CAR T-cell therapy targeted at a specific protein, which has...

Researchers at Texas Children’s Cancer Center and the Center for Cell and Gene Therapy at Baylor College of Medicine, Texas Children’s...

Researchers at Texas Children’s Cancer Center and the Center for Cell and Gene Therapy at Baylor College of Medicine, Texas Children’s...

CAR T cell therapy is a type of immunotherapy that modifies T cells, so they can detect and fight cancer cells. This therapy is...